Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00055913
Status:
COMPLETED
Last Update Posted:
2018-10-02
First Post:
2003-03-06
Brief Title:
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Recurrent Squamous Cell Carcinoma of the Hypopharynx |
| Recurrent Squamous Cell Carcinoma of the Larynx |
| Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity |
| Recurrent Squamous Cell Carcinoma of the Nasopharynx |
| Recurrent Squamous Cell Carcinoma of the Oropharynx |
| Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity |
| Salivary Gland Squamous Cell Carcinoma |
| Stage IV Squamous Cell Carcinoma of the Hypopharynx |
| Stage IV Squamous Cell Carcinoma of the Larynx |
| Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity |
| Stage IV Squamous Cell Carcinoma of the Nasopharynx |
| Stage IV Squamous Cell Carcinoma of the Oropharynx |
| Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity |
Keywords: